Swiss Banks Stock News

Holcim (SWX:HOLN) came into focus after Goldman Sachs shifted its view on the shares from Buy to Neutral, following a strong rally that left the valuation looking full. See our latest analysis for Holcim. The latest CHF78.0 share price comes after a small 1 day share price decline, but that follows an 11.65% 90 day share price return and a very strong 1 year total shareholder return of 73.76%, pointing to momentum that has been building over a longer horizon. That performance also aligns with...

Nestlé has recently drawn attention with multiple developments, including an upcoming February 2026 earnings release, a recall of infant nutrition products over cereulide contamination concerns, reported progress toward selling a stake in its water business, and ongoing exposure to growth in markets such as India’s chocolate sector. Together, these events highlight how Nestlé is simultaneously managing product safety and portfolio reshaping while competing for long-term demand in...

Ypsomed Holding (SWX:YPSN) is back in focus after expanding its collaboration with Becton, Dickinson and Company on a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe that is compatible with YpsoMate 5.5 autoinjectors. See our latest analysis for Ypsomed Holding. At a share price of CHF334.0, Ypsomed Holding has a 90 day share price return of 4.38% and a 5 year total shareholder return of 129.55%. This points to longer term momentum, despite a weaker 1 year total shareholder return of...

Sales acceleration puts BELIMO Holding (SWX:BEAN) in focus BELIMO Holding (SWX:BEAN) reported 2025 sales growth of 23.3% in local currencies, compared with 13.1% in 2024, reaching CHF 1,121 million, a result that has sharpened investor attention on the stock. See our latest analysis for BELIMO Holding. Despite a recent 1-day share price return of 0.79% decline and a 7-day share price return of 2.06% decline, BELIMO Holding’s 12.49% 30-day share price return and 26.56% 1-year total shareholder...

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keenly observing opportunities for undervalued stocks amidst mixed performances across major indices. In this context, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on potential market inefficiencies.

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission...

If you are wondering whether Novartis shares offer solid value at today’s price, this article will walk through what the current market is actually paying for the business. Novartis recently closed at $115.10, with returns of 0.5% over 7 days, 4.5% over 30 days, 6.1% year to date, 32.1% over 1 year, 64.6% over 3 years and 77.8% over 5 years. This gives useful context before you weigh up the valuation. Recent attention on Novartis has been shaped by ongoing product pipeline developments and...

Genentech, part of Roche Holding, has expanded its planned investment in a new biomanufacturing facility in North Carolina to US$2b. The site is intended to increase production capacity for weight loss and metabolic condition treatments. The project is expected to support future demand in metabolic diseases and expand Roche's operational footprint in the U.S. Roche Holding (SWX:ROG) is drawing fresh attention as it commits US$2b to new U.S. manufacturing capacity while its shares trade...

Julius Bär Gruppe (SWX:BAER) has announced a leadership reshuffle, appointing Jean Nabaa as chief operating officer and creating a new Group Communications function led by Cindy Leggett-Flynn, both aimed at supporting the bank’s ongoing transformation. See our latest analysis for Julius Bär Gruppe. These leadership changes come as Julius Bär Gruppe’s share price sits at CHF 67.38, with a 30-day share price return of 7.36% and a stronger 90-day gain of 26.32%. The 1-year total shareholder...

In mid-January 2026, analysts from Kepler Capital and Goldman Sachs reiterated Hold views on Swissquote Group Holding while independent Meyka AI issued a positive rating, citing the company’s AI-driven client automation and personalised trading tools alongside resilient 2025 preliminary results. The commentary underscores how Swissquote’s use of AI, combined with robust net income resilience and ongoing client flows into crypto and margin products, is shaping a differentiated growth story...

Logitech International (SWX:LOGN) has introduced its Rally AI Camera and Rally AI Camera Pro, two AI-powered conference cameras. The new products focus on room usage detection, sustainability features, and integration into managed network environments. The launch marks an expansion of Logitech's video collaboration portfolio aimed at enterprise and education customers. For Logitech, known for its peripherals and video collaboration gear, the Rally AI Camera line extends its presence in...

Partners Group’s new special opportunities push Partners Group Holding (SWX:PGHN) has launched a global special opportunities strategy targeting liquidity driven situations worldwide. The strategy is led by new partner Joshua Hartz and expands the firm’s existing multi strategy private markets platform. See our latest analysis for Partners Group Holding. Partners Group Holding’s CHF1,082.50 share price follows a 10.87% 30-day share price return and 8.55% 90-day share price return. However,...

While SIG Group AG ( VTX:SIGN ) might not have the largest market cap around , it led the SWX gainers with a relatively...

With a price-to-earnings (or "P/E") ratio of 24.9x Galenica AG ( VTX:GALE ) may be sending bearish signals at the...

As of January 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.77%, buoyed by strong economic data and earnings results. In this context of mixed performance across major indices like Germany's DAX and France's CAC 40, identifying stocks that may be trading below their estimated value involves looking for companies with solid fundamentals that could benefit from ongoing economic recovery and favorable trade conditions.

As the European market shows resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are increasingly drawn to dividend stocks for their potential to provide steady income in uncertain times. In this context, selecting a good dividend stock involves considering factors like consistent payout history and financial stability, which can offer a buffer against market volatility.

UBS Group stock moves and current snapshot UBS Group (SWX:UBSG) has drawn investor attention after recent share price moves, with the stock showing mixed shorter term returns but a stronger picture over the past 3 years and 5 years. For context, UBS Group has a market price of CHF 37.42, with reported revenue of $48.2b and net income of $7.3b in its latest annual figures, plus single digit annual revenue growth and higher net income growth. See our latest analysis for UBS Group. Recent moves...

Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid. See our latest analysis for Galderma Group. The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...

In recent days, Genentech, a member of the Roche Group, announced it will more than double its planned investment in a new Holly Springs, North Carolina biomanufacturing facility to about US$2.00 billion, aiming to produce next-generation treatments for metabolic conditions such as obesity by 2029 and support more than 2,000 jobs. This expanded commitment also forms part of Roche and Genentech’s broader US$50.00 billion U.S. manufacturing pledge, highlighting how scale in advanced production...

In mid-January 2026, Novartis reported that the US FDA granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, a fully human monoclonal antibody with a dual B‑cell and BAFF‑R blockade mechanism supported by positive replicate Phase III data. This move positions ianalumab as a potential first targeted therapy in a condition with no approved targeted treatments, highlighting Novartis’s growing focus on complex autoimmune diseases and late-stage specialty medicines. We’ll...

In January 2026, Chocoladefabriken Lindt & Sprüngli AG issued earnings guidance indicating it expects its 2025 operating profit margin to rise at the lower end of a 20–40 basis point improvement range from the previous year’s 16.2%. The company also projected ongoing annual operating margin improvements of 20–40 basis points from 2026 onwards, underscoring a clear emphasis on gradual profitability enhancement. We will now examine how Lindt & Sprüngli’s focus on steady operating margin...

If you are wondering whether Logitech International's current share price still lines up with its fundamentals, you are not alone. The stock recently closed at US$72.48, with returns of a 6.0% decline over 7 days, a 12.7% decline over 30 days, an 8.8% decline year to date, a 9.6% decline over 1 year, a 40.9% return over 3 years, and a 13.7% decline over 5 years, which can change how investors think about both opportunity and risk. Recent coverage has highlighted Logitech International in...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sunrise Communications fair value estimate is CHF55.70 Sunrise...

Key Insights Interroll Holding's estimated fair value is CHF2,626 based on 2 Stage Free Cash Flow to Equity Interroll...